For the quarter, WBA’s sales grew by 12.1% year over year to $34 billion and its earnings per share were $1.27, compared with a loss of $2.05 per share a year ago.
Valens is paying $40 million in cash and stock upfront for Green Roads, with an additional $20 million milestone payment available once the business achieves certain financial milestones.
Lupin received approval for sevelamer hydrochloride tablets, which are indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.